Kaplan–Meier analysis on breast cancer patients revealed MYC amplification was present in 18.2% of patients surveyed, with median overall survival at 135.2 months (95% CI: 113.7–148.1) compared to the unaltered population with median overall survival at 171.3 months (95% CI: 161.2–182.9) (Fig. 7C, Additional files 31 and 32: Tables S6 and S7). The gene discussed is MYC; the disease is breast carcinoma.